

SCYNEXIS, Inc. (NASDAQ: SCYX): Highlights from the RBC Healthcare Conference

Sentiment Indicator : neutral

Posted by Adnan Butt on Tuesday, February 24 2015, 8:35 PM ET

Speakers Marco Taglietti and Yves Ribeill, CEO and President.

Key takeaways: Phase II and Phase I timelines stay unchanged; new leadership has anti-fungal/ antibiotics experience.

- SCY-078 is a new mechanism of action targeting systemic anti-fungal infections, that have a high mortality rate, including against azole and echinocandin resistant organisms.
- First Phase II data showing a step down from an i.v. echinocandin (oral echinocandins are not available) to oral SCY-078, an enfumafungin, are expected in 1H:16.
- First Phase I data for the i.v. formulation are expected by YE:15. An i.v. to oral stepdown would be the optimal presentation for SCY-078.
- Resistance to azoles is increasing and while resistance is less commonplace for echinocandins it is likely to increase as caspofungin (Cancidas) goes generic in 2016.
- A path to a more focused pivotal study with a quicker path to the market remains a possibility pending further discussions with the FDA, especially after initial clinical data are obtained.

Adnan Butt | Adnan.Butt@rbccm.com

[Click here](#) for disclosures for [SCYNEXIS Inc](#), [Adnan Butt](#)

All rights reserved. This material may not be published, broadcast, rewritten or redistributed in any form. Please [click here](#) for legal restrictions and terms of use applicable to this site. Use of this site signifies your agreement to the terms of use.